TAVR Beats Medical Therapy Alone in Severe Pure Aortic Regurgitation Trial

The randomized SEASON-AR trial compared transfemoral TAVR with the VitaFlow system plus guideline-directed medical therapy (GDMT) against GDMT alone in 210 patients with severe pure aortic regurgitation across 18 centers in China. At 1 year, the composite of all-cause death, disabling stroke, or heart failure rehospitalization was significantly lower with TAVR (8.3% vs 24.8%), driven mainly by reduced heart failure rehospitalization, though TAVR was associated with higher rates of major or life-threatening bleeding and new permanent pacemaker implantation, mostly within 30 days.

Most relevant for: Patients with severe pure aortic regurgitation who are considered high risk for or have declined surgical valve replacement.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.